DWA
ATXS

Dorsey Wright & Associates’s Astria Therapeutics ATXS Stock Holding History

Dorsey Wright & Associates’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,042
Closed -$27.2K – 291
2023
Q1 		$27.2K Sell
2,042
-228
-10% -$3.08K 0.01% 169
2022
Q4 		$33.8K Buy
+2,270
New +$23.4K 0.01% 165
2020
Q4 		– Sell
-177
Closed -$7K – 315
2020
Q3 		$7K Sell
177
-59
-25% -$2.34K ﹤0.01% 260
2020
Q2 		$9K Buy
+236
New +$8.4K ﹤0.01% 276

Other funds holding ATXS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Dorsey Wright & Associates's ATXS Position: Q2 2023 in Review

Dorsey Wright & Associates sold out of Astria Therapeutics (ATXS) in Q2 2023, closing a stake of 2,042 shares — an estimated $27.2K sold.

Dorsey Wright & Associates first reported a position in ATXS in Q2 2020 and held it in 4 quarters. The position peaked at $33.8K in Q4 2022. 76 funds tracked by Wall St. Rank hold ATXS as of Q2 2023.

  • Dorsey Wright & Associates reported no remaining Astria Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Dorsey Wright & Associates sold 2,042 Astria Therapeutics shares in Q2 2023, an estimated $27.2K.
  • Dorsey Wright & Associates first reported a position in Astria Therapeutics in Q2 2020 and held it in 4 quarters.
  • Dorsey Wright & Associates's Astria Therapeutics position peaked at $33.8K in Q4 2022.
  • 76 funds tracked by Wall St. Rank held Astria Therapeutics as of Q2 2023.

Based on Dorsey Wright & Associates's 13F filing for Q2 2023, filed 26 Jul 2023.